Envigo’s Barcelona Site Gains AAALAC Accreditation
News Nov 24, 2016
Envigo has announced that its contract research facilities in Barcelona, Spain have been granted full accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council. In a letter to Envigo, AAALAC notified the company that it had met all the conditions required for full accreditation and commended Envigo employees “for providing and maintaining a high quality program of laboratory animal care and use.”
This is the fourth accreditation of Envigo sites in 2016, demonstrating ongoing progress towards the company’s goal to have all of its contract research and research models sites accredited by AAALAC. Recent enhancements of Envigo’s Barcelona facilities in Santiga and Castellar were noted by AAALAC.
As part of an investment in these sites, Envigo recently built a new surgery room, refurbished several key areas used for contract research and animal boarding, as well as installed new facility monitoring systems. The investments and AAALAC accreditation provide customers additional capacity and more flexibility in timelines when placing research studies at various Envigo facilities in Europe and the United States.
John Handley, President of EMEA Operations commented: “This is fantastic news for our research teams in Barcelona and recognition of Envigo’s dedication to the highest standards of care and quality. Securing AAALAC accreditation for another of our European facilities highlights the professionalism and expertise of our employees who work in partnership with our customers to develop products that make the world a healthier and safer place.”
Source: Story from Envigo. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE